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Abstract: Chronic obstructive pulmonary disease (COPD) is common in older people, with 
an estimated prevalence of 10% in the US population aged $75 years. Inhaled medications are 
the cornerstone of treatment for COPD and are typically administered by one of three types of 
devices, ie, pressurized metered dose inhalers, dry powder inhalers, and nebulizers. However, 
age-related pulmonary changes may negatively influence the delivery of inhaled medications 
to the small airways. In addition, physical and cognitive impairment, which are common in 
elderly patients with COPD, pose special challenges to the use of handheld inhalers in the 
elderly. Health care providers must take time to train patients to use handheld inhalers and 
must also check that patients are using them correctly on a regular basis. Nebulizers should be 
considered for patients unable to use handheld inhalers properly. What follows is a review of 
issues associated with COPD and its treatment in the elderly patient.
Keywords: chronic obstructive pulmonary disease, inhaler, device, cognition, disability, 
comorbidities, maintenance therapy
Introduction
Over 10% of the US population aged $75 years report having chronic obstructive 
pulmonary disease (COPD) (Figure 1),1,2 and the primary treatment is inhaled medi-
cations administered with handheld devices or nebulizers.3 The physical and cogni-
tive changes that are common in the elderly, particularly those aged $75 years, may 
interfere with the proper administration of inhaled therapies, resulting in insufficient 
dosing, jeopardizing health outcomes, reducing quality of life, and adding to the 
economic burden of COPD.4 This review examines the special challenges of inhaled 
therapy for COPD in older adults and emphasizes the need for personalized selection 
of treatment for each patient.
Age-related changes in the respiratory system
Age-related physiologic changes contribute to impaired pulmonary function and 
to the increased prevalence of COPD with age. In general, these changes include 
a progressive reduction in compliance of the chest wall, reduction in strength 
of the respiratory muscles, and anatomical changes to the lung parenchyma and 
peripheral airways.5,6 Changes in thorax shape due to osteoporosis and kyphosis 
may induce inefficiencies in chest wall mechanics.5,6 The functional consequences 
of these changes are decreased peak inspiratory and expiratory airflows, vital 
capacity, and efficiency of gas exchange. Hankinson et al studied the spirometry 
results of 4,634 lifetime nonsmoking US adults without a diagnosis or symptoms 






























Figure 1 Prevalence of COPD among adults in the US by age group and gender from 2007 to 2009.1,2 
Abbreviation: COPD, chronic obstructive pulmonary disease.
of chronic pulmonary disease and found that both men 
and women demonstrated a reduction of forced expiratory 
volume in one second (FEV
1
) of about 200–300 mL every 
decade between the ages of 20 and 70 years.7 Based on 
their regression model of the observations in this cross-
sectional study, at age 70 years, FEV
1
 would be expected 
to decrease by about 30% and forced vital capacity (FVC) 
would be expected to decline by about 20% compared 
with values at age 20 years. Importantly, at age 70 years, 
the expected FEV
1
/FVC ratio would be about 74%, a 
value approaching the 70% criterion used for diagnosing 
significant  obstruction.3 Additionally, the area for gas 
exchange declines linearly from the third decade of life and 
is decreased by one third by about age 85 years.5 Loss of 
elastin leads to increases in residual volume and significant 
increases in dead space.5 All of these changes contribute to 
an increased likelihood of COPD in the elderly, and critical 
to geriatric considerations, these age-related changes may 
be less amenable to treatment.
Diagnosis of COPD in the elderly
Any elderly patient who smokes or has a history of smoking 
and demonstrates respiratory symptoms like chronic cough, 
shortness of breath, or physical activity limitations may have 
COPD. Spirometry testing is indicated to confirm the diagno-
sis of COPD and to determine the severity of the disease so 
that appropriate therapy can be initiated. Although most older 
people can perform spirometry adequately,8 some patients 
may be unable to perform this test (eg, patients with cognitive 
impairment, with limitations to vigorous respiratory efforts, 
sedation). Allen and Baxter9 evaluated four tests of cognition 
for their ability to predict inability to perform spirometry in 
a group of 113 subjects aged $70 (range 74–97) years. Only 
five of 57 (9%) subjects with a Mini-Mental State Exami-
nation score below the threshold for borderline cognitive 
impairment (Mini-Mental State Examination score ,2410) 
were able to perform an adequate spirometry test. This 
observation suggests that, in the large majority of patients 
with dementia, the diagnosis of COPD will need to be made 
by clinical means.
In the subset of older patients who are able to perform 
spirometry, a post-bronchodilator FEV
1
/FVC ratio ,0.70 
is considered diagnostic of COPD.3 Table 1 presents the 
Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) classification of severity of COPD based on 
spirometry results.3 This classification or risk assessment 
based on history of COPD exacerbations combined with 
an assessment of symptoms using the Modified British 
Medical Research Council Dyspnea Scale or the COPD 
Assessment Test can be used to assess future risk and 
guide therapeutic decisions (Table 2).3 In patients who are 
unable to perform spirometry, a smoking history of .55 
pack-years, wheezing upon auscultation, and (if available) 
patient self-reported wheezing can be considered evidence 




Treatment of COPD in older adults
 especially  common in nursing home patients, may reduce 
the  effectiveness of  treatment with these devices.13
COPD treatment goals are largely 
unmet in nursing home patients
Recent evidence suggests that the goals of reducing symptoms 
and risks and allowing for an optimal quality of life are largely 
unmet in elderly patients in nursing homes. A retrospective 
analysis of 27,106 nursing home residents with COPD (58% 
female and 65% aged $75 years) by Zarowitz and O’Shea14 
showed that 83% received at least one medication to treat 
COPD. Forty-nine percent of residents were treated with a 
nebulized form of short-acting beta-agonists, and 23% were 
treated with a nebulized form of a short-acting anticholinergic 
medication. The use of handheld inhaler devices was less 
common (15% for short-acting beta-agonists and 2% for 
short-acting anticholinergics). About 42% of this nursing 
home population had moderate or severe cognitive impair-
ment based on the Minimum Data Set Cognitive Performance 
Scale. The preference for nebulized medications suggests that 
the health care providers recognized these residents often 
lacked the physical skills or cognitive abilities to correctly 
use handheld inhaler devices. However, 33% of residents 
demonstrated shortness of breath, and 22% experienced 
at least two exacerbations during the one-year observation 
period, suggesting that there was room for improvement in 
the COPD treatment this group received.
Patients with COPD are often treated with complicated 
regimens,15 and poor eyesight or hearing loss may make 
it more difficult to adhere to treatment. For example, in a 
study of factors associated with poor medication adherence 
in patients with COPD (n=276, average age 71 years), older 
patients reported that being confused about their medications 
Table 1 Classification of severity of airflow limitation in COPD 
based on post-bronchodilator spirometry
GOLD category FEV1
In patients with FEV1/FVC ,0.70
1. Mild Fev1 $80% predicted
2. Moderate 50% #Fev1 ,80% predicted
3. Severe 30% #Fev1 ,50% predicted
4. very severe Fev1 ,30% predicted
Note: Reproduced with permission from the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD).3
Abbreviations: COPD, chronic obstructive pulmonary disease; Fev1, forced 
expiratory volume in one second; FvC, forced vital capacity. 
Table 2 Initial pharmacologic management of COPD
Patient  
category
Characteristics Risk assessment Symptoms Inhaled pharmacologic 








A Low risk 
Fewer symptoms
GOLD 1–2 #1 0–1 ,10 Short-acting anticholinergic as needed or 
Short-acting beta2 agonist as needed
B Low risk 
More symptoms
GOLD 1–2 #1 $2 $10 Long-acting anticholinergic or long-acting  
beta2 agonist
C High risk 
Fewer symptoms
GOLD 3–4 $2 0–1 ,10 Corticosteroid combined with long-acting 
anticholinergic or long-acting beta2 agonist
D High risk 
More symptoms
GOLD 3–4 $2 $2 $10 Corticosteroid combined with long-acting 
anticholinergic or long-acting beta2 agonist
Notes: aMedications in each box are mentioned in alphabetical order. Reproduced with permission from the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD).3
Abbreviations: CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; mMRC score, modified Medical Research Council score. 
of the presence of airflow obstruction.11 In our experience, 
the group of patients who are unable to perform spirometry 
require the greatest attention by the geriatrician in individu-
alizing their treatment.
Treatment of COPD in elderly 
patients
The primary goals of treatment in older persons with COPD 
are maximizing their pulmonary function and preventing 
exacerbations. To address these goals, inhaled medications 
are the primary pharmacologic agents employed,  including 
short-acting and long-acting beta
2
-selective adrenergic 
 agonists, short-acting and long-acting cholinergic antago-
nists, and corticosteroids (Table 2).3,12 These agents are 
typically administered by one of three types of devices, 
ie, pressurized metered dose inhalers (MDIs), dry powder 
inhalers (DPIs), or nebulizers. The age-associated pulmonary 
changes discussed above, especially those affecting inspira-
tory capacity, may negatively influence the pulmonary deliv-
ery of inhaled  medications. Handheld inhalers (ie,  pressurized 
MDIs and DPIs), in particular, pose special challenges 
in elderly patients. Physical and cognitive  impairment, 





or varying the regimen based on how they felt was highly 
correlated with poor medication adherence.16 Anxiety and 
depression, common comorbidities in nursing home patients 
with COPD,17 can also be a major deterrent to therapeutic 
compliance.18,19
Inhaled therapy for COPD poses 
special challenges in elderly adults
Physical and cognitive changes contribute to the difficulties 
some elderly patients have with handheld inhalers.13 An early 
study of cognitively impaired patients who were instructed 
on inhaler use showed that one day after training, 50% of 
patients with borderline cognitive impairment could not 
operate an MDI correctly and 100% of patients with mild 
dementia could not operate an MDI correctly.20
Worsening hypoxia or hypercapnia from COPD or from 
a COPD exacerbation can also negatively impact cognitive 
function, especially in patients who already demonstrate 
mild cognitive dysfunction.21 The hypoxia and hypercapnia 
seem to impact executive function more than orientation 
or memory.22 Therefore, cognitive assessments and inhaler 
use assessments made at the time of discharge after a hos-
pitalization for a COPD exacerbation, when pulmonary and 
associated cognitive functions are likely to be optimal, may 
provide false reassurance that the patient will have sufficient 
cognitive ability to properly manage their COPD. When 
the elderly person with COPD needs to make decisions on 
increasing medications or calling for advice, their decision-
making capacity may be less than at baseline.
Loss of physical strength may contribute to difficulty 
in actuating a pressurized MDI. Gray et al studied a group 
of 72 subjects (aged 50–87 years) and found that decreased 
hand strength (measured with a dynamometer) was an inde-
pendent predictor for incorrect use of a pressurized MDI.23 
 Importantly, they concluded that sufficient hand strength 
beyond the minimum required to actuate the inhaler was 
necessary for correct use. The presence of arthritis or joint 
pain may also contribute to an inability to correctly use a 
handheld inhaler. Neuromuscular conditions like Parkinson’s 
disease or complications after stroke may also interfere with 
use of handheld inhalers.13
Additional factors that contribute to the difficulties faced 
by elderly patients with COPD include their comorbidi-
ties and the complexity of the accompanying medication 
regimens.17 A recent study of 1,003 patients with COPD 
found that the median number of comorbidities was nine and 
that the severity of dyspnea increased with the increasing 
number of comorbid conditions.24 Optimal management of 
the older COPD patient must consider all of their medical 
issues.
Inhaled therapy devices
Multiple inhaled medications for COPD are available and 
are delivered by different devices. The most used devices 
are MDIs, DPIs, and nebulizers. All have limitations, par-
ticularly in elderly adults; error rates increase with age and 
the severity of airflow obstruction.25–27 Within the framework 
of the challenges that elderly patients with COPD face, as 
discussed in the preceding paragraphs, the advantages and 
limitations of these devices for this specific population war-
rant careful clinical consideration when planning optimal 
COPD management.28
Pressurized MDIs
The pressurized MDI is a pressurized aerosol canister that 
contains medication either in solution or suspension in a lique-
fied gas propellant, usually hydrofluoroalkane.29 The primary 
advantages of this device are that it is compact and portable, 
offers consistent dosing and rapid delivery, can be used 
independently and inconspicuously, and sometimes includes 
a dose counter. On the other hand, the pressurized MDI has 
been called the most complex dosage form in medicine.29
Diff iculties using pressurized MDIs are widely 
documented. A meta-analysis of 24 studies of pressurized 
MDI use found that 77% of patients made at least one error 
during its use.12 Inadequate hand-breath coordination, poor 
fine motor control, and hand or finger muscle weakness 
from comorbidity, such as arthritis, stroke, or neuromus-
cular disease, all interfere with proper use. In one study of 
errors associated with pressurized MDIs, the proper use rate 
decreased with increasing age, with only 14% of patients 
aged $75 years using their pressurized MDI correctly 
 (Figure 2).26 Todd et al studied a group of 30 independently 
living, cognitively normal volunteers aged 73–90 years and 
found that 29 of 30 (97%) were able to learn to use a pres-
surized MDI correctly, but when retested 24 hours later, the 
rate of correct use dropped to 36%.30 It is important to note 
that subjects with upper limb weakness were excluded from 
this study. Breath-actuated MDIs may mitigate problems with 
digital manipulation but require sufficient inspiratory flow 
(usually at least 30 L/sec) to trigger the device.31 Different 
inhaler devices require different techniques, so instruction 
for use by providers may not be correct. Spacers are used 
to minimize problems of poor inhalation associated with 
pressurized MDIs, but they present problems of their own. 
The walls of the spacers retain some of the drug, making it 




Treatment of COPD in older adults
Effective dosing with a DPI requires an adequate peak 
inspiratory flow rate, which varies among devices.36,37 An 
initial peak inspiratory flow .30 L/min is considered the 
minimum necessary for effective dosing, and a peak inspira-
tory flow $60 L/min is considered optimal to break up the 
dry powder into particles of ,5 µm diameter that will be 
deposited into the lower airways.37 Older patients, especially 
those over the age of 80 years, may be unable to reach the 
60 L/min threshold.36,37 In a recent study of 213 patients aged 
$60 years (mean 70.1 ± 6.9 years) with advanced COPD 
(FEV
1
 ,50% predicted), 41 (19%) were unable to generate 
the required peak inspiratory flow through the simulated 
resistance of a DPI.38 This subgroup of patients was pre-
dominantly female (80%), were of shorter stature (150 cm), 
and had lower lung capacity (FVC 66% of predicted) than 
the subgroup of patients who were able to generate a peak 
inspiratory flow $60 L/min (48% female, 166 cm tall, and 
FVC 77% of predicted). A low force of inspiration may result 
in insufficient drug deposition in the lung and excessive depo-
sition in the patient’s mouth or pharynx.34,37 This may lead to 
mouth dryness and adversely affect medication  adherence. 
Swallowing the dose that remains in the oropharynx can 
contribute to systemic adverse events. Clinicians should 
spend time teaching patients how to use these devices and 
then confirm appropriate use in follow-up visits.
Nebulizers
The main types of nebulizers can be driven by compressed 
gas (jet nebulizer), an ultrasonically vibrating crystal (ultra-
sonic nebulizer), or a vibrating mesh (membrane). Although 
older devices were bulky, newer models are smaller, portable, 
and battery-operated.13
Once set up, nebulizers are easier for patients to use 
than handheld devices as they only require normal tidal 
respiration for effective drug delivery.39–41 Nebulizers offer 
a convenient way of delivering a higher dose to the airways, 
if necessary.41 The majority of patients in the emergency 
department, hospital, intensive care unit, or walk-in setting 
who need inhaled medication are treated with a nebulizer. 
Nebulizers are also effective for maintenance dosing in 
populations who are unable to use other devices, particularly 
in patients with cognitive, neuromuscular, or ventilatory 
impairments. A large percentage of patients (56%) using 
nebulizers instead of other devices do so because of physical 
or cognitive disabilities.42
The disadvantages cited for nebulizers in the literature 
are not ones of patient use but rather the need for daily 






































Figure 2 Decrease in frequency of successful use of pressurized MDI with patient 
age based on data reported by Giraud and Roche.26 Results are based on physicians’ 
observations of 3955 patients with asthma who were currently being treated with 
an inhaled corticosteroid for at least 3 months and an on-demand short-acting beta-
agonist, both delivered by pressurized MDI. P-value for between-group comparison 
was calculated by Pearson’s Chi-squared test. 
Abbreviation: MDI, metered dose inhaler.
impossible to know how much is actually delivered into the 
airways. Many patients find spacers technically challenging 
and may prefer not to use them.13 The time clinicians spend 
teaching and assessing how patients use these devices is time 
well spent. A scheme for assessment of correct pressurized 
MDI use has been described.32
Dry powder inhalers
The DPI is a breath-actuated device for inhaling medication 
formulated as a dry powder. Advantages of DPIs are that they 
do not require coordination of inhalation with activation and 
do not require hand strength. Therefore, they are easier to 
use than MDIs. Although DPIs are small and portable with 
rapid delivery, their use is nonetheless complex. The DPI 
must be loaded before each inhalation, usually with a capsule 
containing powder. However, opening the blister packs that 
contain the medication capsules is one of the most difficult 
aspects of DPI use for elderly patients.33 Once the capsule 
is loaded, DPIs typically require eight steps for appropriate 
utilization,34 four of which are commonly associated with 
errors (failure to exhale before actuation,34 failure to do a deep 
and rapid inhalation,34,35 lingual blockage of the mouthpiece,34 
failure to hold the breath after inhaling). Patients who are 
cognitively impaired with neurologic alterations, frail, or 
simply unable to follow instructions, are likely to be more 
prone to these errors.





Nebulizer use requires careful instructions on use and 
hygiene, as well as arrangements for maintenance and 
support.43 The assistance of a caregiver is required when 
used by physically or cognitively impaired patients. Despite 
these requirements, a recent survey of 82 patients who were 
using nebulizers found that 98% reported that the benefits 
of nebulizer use outweighed the disadvantages.39 With the 
exception of long-acting anticholinergic drugs, all approved 
classes of medications for COPD are available for administra-
tion by nebulizer (Table 3).3
Choice of inhaled pharmacologic 
treatment in the elderly
Table 2 presents the GOLD classification of risk based on 
spirometry, history of exacerbations, and symptom  severity, 
along with suggested initial inhaled pharmacotherapy for 
Table 3 Available formulations of inhaled COPD medications





 Fenoterol • •
 Levalbuterol • •
 Salbutamol (albuterol) • • •
 Terbutaline •
Long-acting
 Formoterol • • •
 Arformoterol •
 Indacaterol •
 Salmeterol • •
Anticholinergics
Short-acting
 Ipratropium bromide • •








Short-acting beta2 agonists plus  
short-acting anticholinergic
 Fenoterol + ipratropium • •
 Salbutamol + ipratropium • •
Long-acting beta2 agonists plus  
corticosteroids
 Formoterol + budesonide • •
 Salmeterol + fluticasone • •
Note: Reproduced with permission from the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD).3
Abbreviations: COPD, chronic obstructive pulmonary disease; DPI, dry powder 
inhaler; MDI, metered dose inhaler. 
each of the risk classifications.3,12 Table 3 shows the cur-
rently available inhaled formulations of short-acting and 
long-acting beta
2
 agonists, short-acting and long-acting 
anticholinergics, corticosteroids, and various combination 
products.3 Meta-analyses comparing the clinical efficacy of 
medication delivered by pressurized MDIs, DPIs, or nebu-
lizers have failed to show that the method of administration 
impacts outcomes.44 However, it is important to note that 
most studies on MDIs and DPIs have included only patients 
who demonstrated that they could use these devices prop-
erly and excluded patients who were cognitively impaired, 
neurologically altered, or otherwise unable to use the device. 
Therefore, the decision regarding which device should be 
used to treat the elderly COPD patient should be individual-
ized to the patient’s capabilities and preference. Assessment 
of the older person’s ability to use their pressurized MDI or 
DPI should be integrated into the follow-up visit. Patients 
who remain unable to effectively use handheld inhalers 
despite instruction (eg, unable to coordinate inhalation with 
actuation of a pressurized MDI or unable to generate suffi-
cient peak inspiratory flow to use a DPI) should be consid-
ered for nebulizer use. Nebulizers should be considered in 
all patients with cognitive impairment, inadequate manual 
dexterity due to arthritis, Parkinson’s disease, or stroke, or 
who have manual weakness.
Discussion
Treatment of COPD with inhaled therapy should be custom-
ized to each older patient. The selection of inhaler device 
for these patients should be influenced by their cogni-
tive, physical, and educational abilities. MDIs and DPIs 
are the most rapid and most practical way of delivering 
medication. They are the first choice for those patients who 
show that they can follow and, as importantly, remember 
instructions. However, for elderly patients, especially those 
with cognitively impairment and/or with hand arthritis, 
neurologic conditions, or frailty, MDIs and DPIs present 
many challenges. Moreover, confirmation that they are 
using them correctly in follow-up visits is critical. This 
could be a challenge for clinicians with busy schedules, 
and patients may not be adequately overseen. If patients 
cannot use MDIs and DPIs properly, they will not be able 
to properly receive the therapy. These patients should be 
evaluated for nebulized therapy instead. Both rescue and 
maintenance therapies can be delivered with a nebulizer. 
In our experience, failure to prescribe maintenance therapy 
is common, leading to the abuse of rescue medications to 
fulfill maintenance needs.




Treatment of COPD in older adults
Conclusion
In COPD, inhaled therapies are the cornerstone of treat-
ment. While a wide choice of inhalation devices is available, 
patient’s preferences and functional and cognitive capabilities 
may influence the choice of device. Maintenance therapy is 
important to patient outcomes and should be incorporated 
into the treatment plan.
In patients who are prescribed an MDI or DPI, it is incum-
bent on the care team to give instruction to both patients and 
caregivers and assess the use of the device to see whether it is 
being used correctly. Otherwise, nebulizers may be the means 
to provide drugs with the greatest ease for elderly patients.
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